Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Benchmark Statement Prosthetics and Orthotics Services in Lebanon



Lebanese, Syrian and Palestinian people with physical disabilities living in Lebanon are confronted with a variety of barriers that hinder their access to healthcare services especially, rehabilitation services, which include prosthetic and orthotic devices. Furthermore, the absence of a unified and standardized prosthetic and orthotic coverage procedure makes access even more difficult for those individuals.
 
Therefore, the International Committee of Red Cross (ICRC) in Lebanon has worked in close partnership with the Lebanese Ministry of Public Health (MoPH), Lebanese Syndicate of Prosthetics and Orthotics and University of Balamand, with the support of the Rehabskills Limited team, to complete a Benchmark Statement on the Prosthetics and Orthotics Sector in Lebanon (English version).
 
The Benchmark Statement aims at comparing the situation in Lebanon with the World Health Organization (WHO) Standards for Prosthetics and Orthotics as well as making recommendations for its improvement. Consequently, the Benchmark Statement provides a strong foundation that will enable the upgrade of this sector therefore, leading to the establishment of a national strategy for 2030 and regulation of the profession. The Statement covers four main areas of the health system (also known as the four “Ps”): Policy; Products; Personnel and Provision of services. The vision, mission and aims of each ‘P’ will be incorporated into training and mentoring packages that will enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
In April 2021, the ICRC and project partners organized, in collaboration with the Disability Hub, the first online webinar focusing on the Policy area in order to reinforce the visibility and promote the dissemination of the project. The webinar successfully attracted a big number of participants, at a time when health services and systems were and still are severely disrupted in the country due to the Beirut blast, the Covid pandemic, and of course the deteriorating economic situation and political deadlock.



Throughout this year and in 2022, other related online webinars will be organized by the ICRC and project partners to enable the stakeholders to take ownership and work towards ensuring the sustainability and continuation of the Prosthetics and Orthotics Sector in Lebanon.
 
Despite all the difficulties and challenges, Lebanon has taken the first steps on the path of aligning itself with the relevant WHO standards by undertaking this benchmarking process thus, highlighting  its commitment to working towards transforming and improving the provision of prosthetic and orthotic services in the country.
    ...
    55
    ...
ATC Name B/G Ingredients Dosage Form Price
J01MA14 LOXIMED G Moxifloxacin (HCl) - 400mg 400mg Tablet 851,100 L.L
J01MA14 LOXIPHAR G Moxifloxacin (HCl) - 400mg 400mg Tablet 1,063,555 L.L
A07BA01 BIOCARBON B Activated charcoal - 250mg 250mg Tablet 1,361,312 L.L
A07BA51 EUCARBON B Rhubarbe - 25mg, Sulfur - 50mg, Senna - 105mg, Vegetal charcoal - 180mg Tablet 795,555 L.L
C03EA01 MODURETIC B Hydrochlorothiazide - 50mg, Amiloride HCl - 5mg Tablet 767,985 L.L
C09CA04 CONVERIUM G Irbesartan - 300mg 300mg Tablet 585,915 L.L
C10AA07 PMS-ROSUVASTATIN G Rosuvastatin (calcium) - 10mg 10mg Tablet 564,414 L.L
G04CA01 APO-ALFUZOSIN G Alfuzosin HCl - 10mg 10mg Tablet 2,331,567 L.L
N05AH03 OLANZAMED G Olanzapine - 20mg 20mg Tablet 3,941,938 L.L
A02BB01 CYTOTEC B Misoprostol - 200mcg 200mcg Tablet 737,770 L.L
S01EC01 ACETAZOLAMIDE G Acetazolamide - 250mg 250mg Tablet 1,001,163 L.L
A02BB01 MISOFAR G Misoprostol - 200mcg 200mcg Tablet 1,546,763 L.L
J01MA23 BAXDELA B Delafloxacin - 450mg 450mg Tablet 93,777,847 L.L
A02BB01 MISOFAR G Misoprostol - 25mcg 25mcg Tablet 1,855,846 L.L
C09CA04 IRBESARTAN ARROW G Irbesartan - 300mg 300mg Tablet 470,345 L.L
G04CA02 APO-TAMSULOSIN CR G Tamsulosin HCl - 0.4mg 0.4mg Tablet 607,417 L.L
C10AA07 ROVASTIN G Rosuvastatin (calcium) - 10mg 10mg Tablet 618,168 L.L
R03DA11 ANSIMAR G Doxofylline - 400mg 400mg Tablet 544,256 L.L
C09CA06 ATACAND B Candesartan cilexetil - 8mg 8mg Tablet 526,786 L.L
C09CA06 BLOPRESS B Candesartan cilexetil - 8mg 8mg Tablet 847,965 L.L
N06CA02 SERNIL G Flupentixol - 0.5mg, Melitracen - 10mg Tablet 1,003,402 L.L
C09CA06 ANDESART 8 G Candesartan cilexetil - 8mg 8mg Tablet 498,566 L.L
N02BE01 PARANOR G Paracetamol - 650mg 650mg Tablet 162,605 L.L
C09CA06 ARKANDA 8 G Candesartan cilexetil - 8mg 8mg Tablet 639,925 L.L
N06DA02 ALZEPIL G Donepezil HCl - 5mg 5mg Tablet 1,406,555 L.L
N02BE51 SICADOL EXTRA G Paracetamol - 500mg, Caffeine - 65mg Tablet 147,823 L.L
N05AH03 ZYPREXA B Olanzapine - 10mg 10mg Tablet 1,468,820 L.L
R03DB05 THEODEX G Ipeca fluide extract - 20mg, Aminophylline - 150mg, Caffeine - 100mg, Ephedrine - 15mg Tablet 156,142 L.L
C09CA06 ATACAND B Candesartan cilexetil - 16mg 16mg Tablet 705,517 L.L
C10AA07 APO-ROSUVASTATIN G Rosuvastatin (calcium) - 20mg 20mg Tablet 670,577 L.L
    ...
    55
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025